GleamWall
中文EN

ASBP Aspire-Lakewood Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1847345 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY41.6%
TTM EPS YoY201.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-25.0%
Operating margin-7,494.8%
Net margin-11,314.1%
FCF margin—
EBITDA margin—

Returns

ROE-1,032.1%
ROA-152.1%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets13.2%
Debt / equity0.00x
Current ratio7.99x
Interest coverage-0.79x

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-53.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$6,202—
Cost of revenue$6,318—
Gross profit-$116—
R&D expense$923,914$144,356
SG&A expense$17.64M$940,421
Operating income-$19.35M-$1.21M
Interest expense$8.53M$97,988
Pretax income-$24.48M-$1.31M
Income tax—$1,013
Net income-$24.48M-$1.31M
EPS (diluted)-16.38-1.90
Weighted avg. shares (diluted)1.49M689,913
Balance sheet
Cash & equivalents$1.00M$3,633
Inventory$253,160—
Current assets$1.31M$147,989
Total assets$1.31M$147,989
Current liabilities$7.59M$1.69M
Total liabilities$7.69M$1.69M
Shareholders' equity-$6.38M-$1.54M
Shares outstanding117,780690,044
Cash flow statement
Operating cash flow-$4.92M-$265,186
Investing cash flow—$13.78M
Financing cash flow$5.92M$257,645
Stock-based compensation$14.13M$0
Share buybacks—$13.78M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.